Given the crucial role of HLA in cancer-specific antigen presentation and subsequent T-cell activation, our findings suggest that the high expression of LCMR1 in LCLC could lead to immune checkpoint escape by inhibiting HLA expression, ultimately leading to poor prognosis. Here, MED19 is linked to cancer.